CA1247538A
(en)
*
|
1982-05-21 |
1988-12-28 |
Mark C. Glassy |
Human-human hybridomas for solid tumors
|
US4618577A
(en)
*
|
1983-02-09 |
1986-10-21 |
The Regents Of The University Of California |
Human-human hybridoma, CLNH5
|
ATE56046T1
(de)
*
|
1983-03-04 |
1990-09-15 |
Health Research Inc |
Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.
|
US4939240A
(en)
*
|
1983-03-04 |
1990-07-03 |
Health Research, Inc. |
Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
|
US4613576A
(en)
*
|
1983-03-09 |
1986-09-23 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies to cancer cells
|
US4693966A
(en)
*
|
1983-03-11 |
1987-09-15 |
Sloan-Kettering Institute For Cancer Research |
Human monoclonal antibodies from lymphocytes of patients with malignant melanoma
|
GB2140030A
(en)
*
|
1983-04-08 |
1984-11-21 |
Kureha Chemical Ind Co Ltd |
Monoclonal antibody to human urinary bladder cancer
|
WO1985002411A1
(en)
*
|
1983-11-25 |
1985-06-06 |
The University Of Melbourne |
Cell line and monoclonal antibody
|
NZ210867A
(en)
*
|
1984-01-31 |
1989-01-06 |
Litton Bionetics Inc |
Tumour-specific monoclonal antibodies, production thereof and use
|
US4886745A
(en)
*
|
1984-03-30 |
1989-12-12 |
Syntex Inc. |
Monoclonal antibody specific for human basal cell surface antigen
|
AU4070685A
(en)
*
|
1984-03-30 |
1985-10-03 |
Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibody specific for human basal cell surfaces
|
JPS6133125A
(ja)
*
|
1984-07-25 |
1986-02-17 |
Morinaga & Co Ltd |
ヒト単クロ−ン性抗肺ガン細胞抗体
|
US4761377A
(en)
*
|
1984-10-15 |
1988-08-02 |
The Regents Of The University Of California |
Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
|
EP0183876A1
(en)
*
|
1984-11-27 |
1986-06-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Monoclonal antibodies for endotoxin core and their use
|
US5106746A
(en)
*
|
1985-05-22 |
1992-04-21 |
E. I. Du Pont De Nemours And Company |
Process for the in vitro immunization of human splenocytes against tumor associated antigens
|
US5776093A
(en)
|
1985-07-05 |
1998-07-07 |
Immunomedics, Inc. |
Method for imaging and treating organs and tissues
|
JPH0655680B2
(ja)
*
|
1985-10-26 |
1994-07-27 |
萩原 義秀 |
悪性腫瘍用ヒトモノクロナル抗体複合剤
|
EP0222360A3
(en)
*
|
1985-11-12 |
1989-03-15 |
Biotherapeutics Inc. |
A method of producing a patient-specific cytotoxic reagent and composition
|
JPH0767388B2
(ja)
*
|
1986-01-13 |
1995-07-26 |
三菱化学株式会社 |
抗体産生細胞株の樹立方法
|
WO1991009135A1
(en)
*
|
1989-12-18 |
1991-06-27 |
Board Of Regents, The University Of Texas System |
Tumor-specific, cell surface-binding monoclonal antibodies
|
US5281710A
(en)
*
|
1990-08-01 |
1994-01-25 |
The Scripps Research Institute |
Dynemicin analogs: synthesis, methods of preparation and use
|
JPH04346792A
(ja)
*
|
1991-05-22 |
1992-12-02 |
Hagiwara Yoshihide |
抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするdna塩基配列
|
EP0528663B1
(en)
*
|
1991-08-16 |
1997-10-29 |
Kabushiki Kaisha Toshiba |
Monoclonal antibody to a synaptophysin
|
DK1004315T3
(da)
|
1997-08-15 |
2008-07-21 |
Chugai Pharmaceutical Co Ltd |
Forebyggende midler og/eller lægemidler indeholdende anti-IL6-receptorneutraliserende antistoffer til reduktion af urinproteinudskillelsen ved systemisk lupus erythematosus
|
ES2307526T3
(es)
|
1999-08-23 |
2008-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
Potenciadores de la expresion del antigeno hm1.24.
|
CA2388408A1
(en)
|
1999-10-01 |
2001-04-12 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
US7931897B2
(en)
|
2001-02-07 |
2011-04-26 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for hematopoietic tumors
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
AU2003211990A1
(en)
|
2002-02-14 |
2003-09-04 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
AU2003257536A1
(en)
|
2002-08-27 |
2004-03-19 |
Chugai Seiyaku Kabushiki Kaisha |
Method of stabilizing protein solution preparation
|
ES2558303T3
(es)
|
2002-09-11 |
2016-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Método de purificación de proteínas
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP1642971B1
(en)
|
2003-06-18 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Fucose transporter
|
EP1652923B1
(en)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
US8298816B2
(en)
|
2003-12-03 |
2012-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
Expression systems using mammalian beta-actin promoter
|
JPWO2005056605A1
(ja)
|
2003-12-12 |
2007-12-06 |
中外製薬株式会社 |
3量体以上の受容体を認識する改変抗体
|
CN111925445A
(zh)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
抗-磷脂酰肌醇蛋白聚糖3抗体
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
EP1870459B1
(en)
|
2005-03-31 |
2016-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
CN101237890A
(zh)
|
2005-06-10 |
2008-08-06 |
中外制药株式会社 |
含有葡甲胺的蛋白质制剂的稳定剂及其利用
|
CN101330929B
(zh)
|
2005-10-14 |
2014-03-05 |
学校法人福冈大学 |
胰岛移植中的移植胰岛障碍抑制剂
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
EP3135298B1
(en)
|
2006-01-27 |
2018-06-06 |
Keio University |
Therapeutic agents for diseases involving choroidal neovascularization
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
WO2007119796A1
(ja)
|
2006-04-14 |
2007-10-25 |
Medical And Biological Laboratories Co., Ltd. |
エフェクター機能を有するポリペプチド変異体
|
RU2511406C2
(ru)
|
2006-06-08 |
2014-04-10 |
Чугаи Сейяку Кабусики Кайся |
Профилактическое или лекарственное средство для воспалительного заболевания
|
US20100040600A1
(en)
|
2006-06-14 |
2010-02-18 |
Chugai Seiyaku Kabushiki Kaisha |
Agents for Promoting the Growth of Hematopoietic Stem Cells
|
PE20081004A1
(es)
|
2006-07-13 |
2008-09-18 |
Chugai Pharmaceutical Co Ltd |
Agentes inductores de muerte celular
|
WO2008010556A1
(fr)
|
2006-07-21 |
2008-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Médicament agissant contre une maladie rénale
|
DE602006013809D1
(de)
|
2006-07-24 |
2010-06-02 |
Facultad De Medicina Universid |
Antikörper, Antikörperfragmente und scFv die an posttranslational modifizierte Neurotrophine binden
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
JPWO2008032833A1
(ja)
|
2006-09-14 |
2010-01-28 |
株式会社医学生物学研究所 |
Adcc活性を増強させた抗体及びその製造方法
|
US9017684B2
(en)
|
2006-10-12 |
2015-04-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-EREG antibody
|
AU2007311957A1
(en)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
US20100111851A1
(en)
|
2007-01-05 |
2010-05-06 |
The University Of Tokyo |
Diagnosis and treatment of cancer by using anti-prg-3 antibody
|
JP5374360B2
(ja)
|
2007-02-27 |
2013-12-25 |
中外製薬株式会社 |
抗grp78抗体を有効成分として含む医薬組成物
|
US8722858B2
(en)
|
2007-06-25 |
2014-05-13 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-Prominin-1 antibody having ADCC activity or CDC activity
|
US20100129355A1
(en)
|
2007-07-26 |
2010-05-27 |
Osaka University |
Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
EP2196220B1
(en)
|
2007-10-02 |
2014-12-03 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibting anti-IL-6 receptor antibody for treating graft-versus-host disease
|
WO2009054435A1
(ja)
|
2007-10-24 |
2009-04-30 |
Otsuka Chemical Co., Ltd. |
増強されたエフェクター機能を有するポリペプチド
|
US8680243B2
(en)
|
2007-11-14 |
2014-03-25 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
US9175091B2
(en)
|
2007-11-15 |
2015-11-03 |
Chugai Seiyaku Kabushiki Kaisha |
Monoclonal antibody capable of binding to anexelekto, and use thereof
|
KR101595134B1
(ko)
|
2007-12-05 |
2016-02-17 |
추가이 세이야쿠 가부시키가이샤 |
소양증 치료제
|
AU2008332271C1
(en)
|
2007-12-05 |
2014-04-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-NR10 antibody and use thereof
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
BRPI0907237A2
(pt)
|
2008-01-11 |
2015-07-14 |
Univ Tokyo |
Anticorpo anti-cldn6
|
PL2708558T3
(pl)
|
2008-04-11 |
2018-09-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny
|
EP2116261A1
(en)
|
2008-05-07 |
2009-11-11 |
Institut Pasteur |
Sub-region of a plasmodium protein with improved vaccine potential and medical uses thereof
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
CA2728243C
(en)
|
2008-06-05 |
2020-03-10 |
National Cancer Center |
Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
|
EP2319869B1
(en)
|
2008-06-20 |
2016-08-17 |
National University Corporation Okayama University |
ANTIBODY AGAINST OXIDIZED LDL/ß²GPI COMPLEX AND USE OF THE SAME
|
CN102395603A
(zh)
|
2008-12-26 |
2012-03-28 |
国立大学法人东京大学 |
使用抗lgr7抗体的癌症的诊断和治疗
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
AU2010242338B2
(en)
|
2009-05-01 |
2013-12-19 |
Perseus Proteomics Inc. |
Anti-cadherin antibody
|
US20120141501A1
(en)
|
2009-05-29 |
2012-06-07 |
Forerunner Pharma Research Co. Ltd |
Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
WO2011099524A1
(ja)
|
2010-02-10 |
2011-08-18 |
富士フイルムRiファーマ株式会社 |
放射性金属標識抗カドヘリン抗体
|
US20120321557A1
(en)
|
2010-02-26 |
2012-12-20 |
Forerunner Pharma Research Co., Ltd. |
Anti-icam3 antibody and use thereof
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
DK2578231T3
(da)
|
2010-05-28 |
2022-12-12 |
Chugai Pharmaceutical Co Ltd |
Antitumor-t-celle-reaktionsforstærker
|
CA2816021A1
(en)
|
2010-10-25 |
2012-05-10 |
Regents Of The University Of Minnesota |
Therapeutic composition for treatment of glioblastoma
|
DK2634194T3
(en)
|
2010-10-29 |
2018-10-01 |
Perseus Proteomics Inc |
ANTI-CDH3 ANTIBODY WITH HIGH INTERNALIZATION CAPACITY
|
EP2735315B1
(en)
|
2011-07-19 |
2019-10-02 |
Chugai Seiyaku Kabushiki Kaisha |
Stable protein-containing preparation containing argininamide or valinamide
|
US9550835B2
(en)
|
2011-08-23 |
2017-01-24 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DDR1 antibody having anti-tumor activity
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EP2772268B8
(en)
|
2011-10-28 |
2020-01-08 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
CN104011207B
(zh)
|
2011-10-31 |
2018-09-18 |
中外制药株式会社 |
控制了重链与轻链的缔合的抗原结合分子
|
JP6113717B2
(ja)
|
2012-04-04 |
2017-04-12 |
株式会社ペルセウスプロテオミクス |
抗cdh3(p−カドヘリン)抗体の薬剤コンジュゲート
|
JP6519851B2
(ja)
|
2012-07-06 |
2019-05-29 |
京都府公立大学法人 |
眼細胞の分化マーカーおよび分化制御
|
RU2673943C2
(ru)
|
2012-09-27 |
2018-12-03 |
Чугаи Сейяку Кабусики Кайся |
Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
|
US10782290B2
(en)
|
2013-06-11 |
2020-09-22 |
National Center Of Neurology And Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
|
EP3581179A1
(en)
|
2013-12-27 |
2019-12-18 |
Chugai Seiyaku Kabushiki Kaisha |
Fgfr gatekeeper mutant gene and drug targeting same
|
EP4056993A1
(en)
|
2014-08-20 |
2022-09-14 |
Chugai Seiyaku Kabushiki Kaisha |
Method for measuring viscosity of protein solution
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
TW202339800A
(zh)
|
2015-02-27 |
2023-10-16 |
日商中外製藥股份有限公司 |
Il-6受體抗體用於製備醫藥組成物的用途
|
AU2018240938A1
(en)
|
2017-03-24 |
2019-10-10 |
Zenyaku Kogyo Co., Ltd. |
Anti-IgM/B cell surface antigen bispecific antibody
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
MA55090A
(fr)
|
2019-02-28 |
2022-01-05 |
Juntendo Educational Found |
Anticorps capable de se lier à la calréticuline mutante tronquée, et médicament de diagnostic, prophylactique ou thérapeutique pour néoplasmes myéloprolifératifs
|
TW202110477A
(zh)
|
2019-04-17 |
2021-03-16 |
國立大學法人廣島大學 |
以組合投予il-6 抑制劑與ccr2 抑制劑為特徵之泌尿器官癌的治療劑
|
EP3984554A4
(en)
|
2019-06-11 |
2023-11-08 |
ONO Pharmaceutical Co., Ltd. |
IMMUNOSUPPRESSION AGENT
|
JPWO2021206078A1
(sr)
|
2020-04-06 |
2021-10-14 |
|
|
EP4190354A1
(en)
|
2020-07-28 |
2023-06-07 |
Chugai Seiyaku Kabushiki Kaisha |
Prefilled syringe preparation with needle, provided with needle shield and including novel modified antibody
|
JPWO2022045247A1
(sr)
|
2020-08-27 |
2022-03-03 |
|
|
AU2022232856A1
(en)
|
2021-03-12 |
2023-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|